Kamada SG&A Expenses 2012-2024 | KMDA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Kamada sg&a expenses from 2012 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Kamada sg&a expenses from 2012 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$172.8B
Vertex Pharmaceuticals (VRTX)	$125.8B
Regeneron Pharmaceuticals (REGN)	$111.1B
Bristol Myers Squibb (BMY)	$108.2B
Gilead Sciences (GILD)	$108B
CSL (CSLLY)	$97B
GSK (GSK)	$81.3B
Alnylam Pharmaceuticals (ALNY)	$38.6B
Argenex SE (ARGX)	$32.3B
BioNTech SE (BNTX)	$28B
Biogen (BIIB)	$27.5B
Illumina (ILMN)	$22.9B
Moderna (MRNA)	$22.1B
BeiGene (BGNE)	$21.6B
Genmab (GMAB)	$15B
BioMarin Pharmaceutical (BMRN)	$13.3B
Insmed (INSM)	$13.2B
Vaxcyte (PCVX)	$13.2B
Exact Sciences (EXAS)	$13B
Incyte (INCY)	$12.7B
Sarepta Therapeutics (SRPT)	$12B
Bio-Techne Corp (TECH)	$11.4B
QIAGEN (QGEN)	$9.9B
Bio-Rad Laboratories (BIO.B)	$9.3B
Roivant Sciences (ROIV)	$8.9B
Revolution Medicines (RVMD)	$8.4B
Exelixis (EXEL)	$8.4B
Intra-Cellular Therapies (ITCI)	$8B
Legend Biotech (LEGN)	$8B
Ascendis Pharma (ASND)	$7.9B